Putting risk in oerspective: Do people make
better decisions when they understand
average risk?
Newswise — If there were a pill that would cut your risk of
breast cancer in half, would you take it?
What if you were told your risk of breast
cancer was already below average?
In a newly published survey, women who were told their risk
of breast cancer was above average were more
likely to endorse taking the hypothetical
pill than women who were told their risk was
below average. The above average group was
also more likely to believe that the pill
significantly reduced breast cancer risk –
even though both groups were told the pill
would cut their risk of breast cancer in
half.
Researchers from the University of Michigan Comprehensive
Cancer Center surveyed 249 random women in a
hospital cafeteria. Participants were given
a scenario in which their own risk of breast
cancer was 6 percent. Then, half of the
women were told the average woman’s risk of
breast cancer was 12 percent; the other half
were told the average risk was 3 percent.
Both groups were told in the hypothetical scenario that there
was a pill that would reduce their breast
cancer risk to 3 percent, but it caused side
effects including hot flashes in most women,
with a small risk of cataracts, stroke or
heart attack. They were then asked to say if
they would take the pill, given their risk
of breast cancer.
No matter what their decision, 62 percent of the women said
the average risk information was helpful in
making a decision about whether to take the
drug.
But, the study authors contend, this influence could be
dangerous. After all, if a prevention
strategy reduces a person’s risk by half,
does it matter if others receive more or
less benefit?
“What’s really important is to focus on your risk and the
benefits you could get from a treatment.
Knowing how one’s own risk compared to the
average woman’s risk actually changed
people’s decisions. It’s very worrisome that
this piece of information had an influential
impact on a woman’s perceptions of a breast
cancer prevention drug,” says study author
Angela Fagerlin, Ph.D., research assistant
professor of internal medicine at the U-M
Medical School and an investigator at the VA
Ann Arbor Healthcare System.
Results of the study appear in the December issue of
Patient Education and Counseling.
The study authors argue that comparing individual risk
against average could lead people to make
poor decisions. For example, below-average
risk does not mean zero risk, yet low-risk
women might think they can skip their yearly
mammogram. On the other hand, women at
high-risk might undergo risky treatments
that they might otherwise not have chosen.
“When you give women their five-year risk of breast cancer,
it might be 3 percent, and that 3 percent
seems really low. But the way women tend to
use comparative information is worrisome.
They’re focusing too much on where they
stack up against average and they disregard
their own individual risk information what
that risk means to them,” says Fagerlin, a
member of the U-M Center for Behavioral and
Decision Sciences in Medicine.
The study authors urge doctors and health educators to use
average risk carefully when discussing
individual patients’ options.
“People should focus on what their own risk is – how does
that risk feel to them, and what do they
think of their treatment or prevention
strategies. We believe that when making a
medical decision, people should consider the
risks and benefits of their prevention or
treatment options and they should make the
best decision based on their perceptions of
those risks and benefits. The decision
should not be influenced by whether their
risks or benefits are greater or less than
another person,” Fagerlin says.
The risk estimates used in the study were fictitious. The
drug mentioned is modeled after tamoxifen,
which can be given to women at high risk of
breast cancer to help prevent the disease.
The average woman’s lifetime risk of breast
cancer is 12.7 percent, or one in eight. But
an individual’s five-year risk of breast
cancer will vary based on family history,
environmental exposures and lifestyle
issues. Some 178,480 women will be diagnosed
with breast cancer this year and more than
40,000 will die from the disease.
For information about breast cancer risk or screenings, visit
mcancer.org or call the U-M Cancer
AnswerLine at 800-865-1125.
In addition to Fagerlin, study authors were Brian Zikmund-Fisher,
Ph.D., and Peter Ubel, M.D., both of the VA
Ann Arbor Healthcare System and the
University of Michigan Medical School.
Funding for the study was from the National Institutes of
Health. Fagerlin is supported by an award
from the U.S. Department of Veterans Affairs
and Zikmund-Fisher is supported by an award
from the American Cancer Society.